Profusa gets Nasdaq approval to move listing to Capital Market tier, pending milestones by July 6, 2026

Profusa, a digital health company specializing in continuous biochemical monitoring, received approval from the Nasdaq Hearings Panel to transfer its stock listing from The Nasdaq Global Market to The Nasdaq Capital Market. This move is conditional on Profusa meeting certain interim milestones and complying with bid price and stockholders' equity requirements by July 6, 2026. The company focuses on innovative biosensors and data platforms for personalized medical data. This transition aims to maintain its Nasdaq listing while it works on meeting financial standards.